P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Tengfei Li(United States Food and Drug Administration), Mark A. Socinski(Florida Hospital Cancer Institute), Yunpeng Liu(First Hospital of China Medical University), S. Shpyro(BioNTech (Germany)), Ping‐Ying Pan(Houston Methodist), Hsin‐Jen Chen(Cancer Institute (WIA)), Sergey Efuni(Oncoceutics (United States)), Olufunmilayo I. Fawole(Florida Cancer Specialists & Research Institute), John Hamm(Ontario Institute for Cancer Research), Z. Liu(Southern Medical University), B.C. Cho(Seoul Medical Center), Jennifer L. Leddon(University of Cincinnati), Bo Yang(Tongji Hospital), Ping Zheng(Oncoceutics (United States)), Qiang Wang(BioNTech (Germany)), Jing Zhang(Guangzhou University of Chinese Medicine), Kun He(Tongji University), Yuan Wu(Jiangsu Cancer Hospital), Yangqing Huang(Shanghai Public Health Clinical Center), Yu Xiao(Xi'an Jiaotong University), R. Balaraman(Munroe Regional Medical Center), Wubin Long(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital)
Cited by 1
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k